Provided by Tiger Trade Technology Pte. Ltd.

iBio

1.43
-0.0400-2.72%
Post-market: 1.430.00000.00%19:56 EDT
Volume:755.21K
Turnover:1.11M
Market Cap:71.04M
PE:-2.55
High:1.50
Open:1.46
Low:1.42
Close:1.47
52wk High:3.82
52wk Low:0.7440
Shares:49.68M
Float Shares:34.88M
Volume Ratio:0.56
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5600
EPS(LYR):-1.7504
ROE:-62.09%
ROA:-34.50%
PB:0.92
PE(LYR):-0.82

Loading ...

iBio Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
Apr 28

iBio amends 8-K to correct Series G warrants expiration date to May 20, 2026

Reuters
·
Apr 18

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
Apr 09

Ibio (IBIO) Receives a Buy from Chardan Capital

TIPRANKS
·
Apr 09

Validating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition

TIPRANKS
·
Apr 09

BUZZ-U.S. STOCKS ON THE MOVE-Delta, GATX, Humana

Reuters
·
Apr 08

iBio receives regulatory clearance to initiate IBIO-600 trial in Australia

TIPRANKS
·
Apr 08

BUZZ-iBio rises as obesity drug gets first green light for human trial in Australia

Reuters
·
Apr 08

iBio wins Australian TGA clearance for Phase 1 IBIO-600 trial

Reuters
·
Apr 08

Ibio Inc - Phase 1 Trial of Ibio-600 to Begin Dosing in Q2 2026

THOMSON REUTERS
·
Apr 08

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

GlobeNewswire
·
Apr 08

Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans

GlobeNewswire
·
Apr 04

iBio Chief Legal Officer Marc Banjak acquires common shares; $23,028 value

Reuters
·
Mar 28

iBio (IBIO-610): Validated Activin E Mechanism, Strategic Trial Positioning, and Attractive Risk-Reward Support a Buy Rating

TIPRANKS
·
Mar 27

iBio CFO Felipe Duran buys USD 50,000 of common shares

Reuters
·
Mar 23

iBio CEO and CSO Martin Brenner acquires USD 24,919 of common shares

Reuters
·
Mar 23

Ibio (IBIO) Receives a Buy from LifeSci Capital

TIPRANKS
·
Mar 21

Buy Rating on iBio Driven by Differentiated Activin-Targeting Antibody and Large PH-HFpEF Market Opportunity

TIPRANKS
·
Mar 19

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 18

Ibio Inc - Expects to Declare Bispecific Antibody Candidate for Ph-Hfpef in Q3 2026

THOMSON REUTERS
·
Mar 17